Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis

Journal of Clinical Rheumatology

Volumn 18, Issue 1, 2012, Pages 39-41

  Arulkumaran, Nishkantha ^a   Suleman, Rashid ^a   Cecconi, Maurizio ^a   Kiely, Patrick ^b   Chua, Felix ^a  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b Rheumatology Department   (United Kingdom)

Author keywords

ANCA associated asculitis; rituximab; rituximab induced pneumonitis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; HEMOGLOBIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB;

AGED; ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BRONCHOSCOPY; CASE REPORT; CAUCASIAN; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CREATININE BLOOD LEVEL; DIALYSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; GRANULOMATOSIS; HEMOGLOBIN BLOOD LEVEL; HEMOPTYSIS; HUMAN; HUMAN TISSUE; HYPOXIA; INTENSIVE CARE; LOW DRUG DOSE; LUNG LAVAGE; MAINTENANCE THERAPY; MALAISE; MALE; MEDICAL HISTORY; MICROSCOPIC POLYANGIITIS; NONINVASIVE VENTILATION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; SINUS CONGESTION; THORAX RADIOGRAPHY; URINE SEDIMENT;

AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; MALE; PNEUMONIA; PREDNISOLONE; TOMOGRAPHY, X-RAY COMPUTED; WEGENER GRANULOMATOSIS;

EID: 84855201765     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31823ee5bf     Document Type: Article

References (14)

1. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337:1512-1523. (Pubitemid 27495778)
2. Casian A, Jayne D. Management of alveolar hemorrhage in lung vasculitides. Semin Respir Crit Care Med. 2011;32:335-345.
3. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2011 [Epub ahead of print].
4. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med.2010;363:211-220.
5. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221-232.
6. Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapyVrare but there! Leuk Lymphoma. 2009;50:1083-1095.
7. Liote H, Liote F, Seroussi B, et al. Rituximab-induced lung disease: A systematic literature review. Eur Respir J. 2010;35:681-687.
8. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
9. Eisenbeis CF, Caligiuri MA, Byrd JC. Rituximab: Converging mechanisms of action in non-Hodgkin's lymphoma? Clin Cancer Res. 2003;9:5810-5812. (Pubitemid 38018061)
10. Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature. Pediatr Pulmonol. 2009;44:922-934.
11. Selenko N, Maidic O, Draxier S, et al. CD20 antibody (C2B8)Yinduced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia. 2001;15:1619-1626. (Pubitemid 32994682)
12. Liote H, Cadranel J, Liote F. Rituximab-induced pneumonitis: Steroid therapy or not? Pediatr Pulmonol. 2010;45:412-413; author reply 414-416.
13. Akoun GM, Cadranel JL, Rosenow EC 3rd, et al. Bronchoalveolar lavage cell data in drug-induced pneumonitis. Allerg Immunol (Paris). 1991;23:245-252.
14. Hamada K, Nagai S, Kitaichi M, et al. Cyclophosphamide-induced late-onset lung disease. Intern Med. 2003;42:82-87. (Pubitemid 36267671)